Icariside II is a glycosyloxyflavone that is 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone in which the hydroxy group at position 3 has been converted into its alpha-L-rhamnopyranoside.
Definición
Icariside II is a glycosyloxyflavone that is 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone in which the hydroxy group at position 3 has been converted into its alpha-L-rhamnopyranoside. It has a role as an antineoplastic agent, an anti-inflammatory agent, an apoptosis inducer and a plant metabolite. It is functionally related to an alpha-L-rhamnopyranose.
Fuente: PubChem
Funciones cosméticas
Referencias de seguridad y regulación
Other restriction: ban substances that deplete the ozone layer
Más datos: nombres, identificadores, propiedades, ensayos y literatura
Nombres y definiciones oficiales
Nombre de etiquetado de la JCIA イカリシドⅡ: 本品は、次の化学式で表される有機化合物である。
Nombres e identificadores
- CAS No.número de registro químico
- 113558-15-9
- DTXSIDidentificador químico de la EPA (EE. UU.)
- DTXSID40150457
- DTXCIDidentificador de compuesto de la EPA (EE. UU.)
- DTXCID4072948
- IUPAC
- 5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4H-1-benzopyran-3-yl 6-deoxy-alpha-L-mannopyranoside
- Fórmula molecular
- C27H30O10
- Peso molecular
- 514.527 g/mol
Para qué lo usan los productos
Usos de los 5 productos declarados ante la EPA de EE. UU. con este ingrediente. Incluye productos que no son cosméticos, así que las primeras filas son sus usos principales.
- Softener and conditioner2
- Bleaching agent1
- Humectant1
- Antioxidant1
Fuente: Panel CompTox de la EPA
Literatura relacionada
- Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer · 2023
- Epimedium brevicornum Maxim. Extract exhibits pigmentation by melanin biosynthesis and melanosome biogenesis/transfer · 2022
- Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF. · 2020
- Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells. · 2014
- Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells. · 2013